Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the effect of castor oil versus placebo on intestinal permeability in healthy individuals.
Randomized, parallel-group, placebo-controlled, blinded, dose-response study using Castor oil and see the effects it has on small bowel and colonic permeability measured in healthy female and male adults.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 750 mg castor oil treatment group | Experimental | Subjects will take ricinoleic acid daily on an empty stomach in the morning 30 minutes before breakfast for a total of 4 days |
|
| 1500 mg castor oil treatment group | Experimental | Subjects will take ricinoleic acid daily on an empty stomach in the morning 30 minutes before breakfast for a total of 4 days |
|
| 3000 mg castor oil treatment group | Experimental | Subjects will take ricinoleic acid daily on an empty stomach in the morning 30 minutes before breakfast for a total of 4 days |
|
| Placebo group | Placebo Comparator | Subjects will take placebo daily on an empty stomach in the morning 30 minutes before breakfast for a total of 4 days |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ricinoleic Acid 750 mg | Dietary Supplement | 750 mg administered orally |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Change in urinary excretion of 13^C-mannitol | Percent urinary excretion of 13^C-mannitol | 0-2 hours, 2-8 hours and 8-24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Change in urinary excretion of lactulose | Percent urinary excretion of lactulose | 0-2 hours, 2-8 hours and 8-24 hours |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Michael Camilleri, MD | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic Minnesota | Rochester | Minnesota | 55905 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C030521 | ricinoleic acid |
Not provided
Not provided
Not provided
Prospective randomized, placebo-control study of effect of castor oil on intestinal and colonic permeability
Not provided
Not provided
Not provided
| Ricinoleic Acid 1500 mg |
| Dietary Supplement |
1500 mg administered orally |
|
| Ricinoleic Acid 3000 mg | Dietary Supplement | 3000 mg administered orally |
|
| Placebo | Drug | Contains no active ingredient. |
|